Preliminary Data from a Study on Polymorphism RS4244285 of P4502c19 Cytochrome Gene in Patients with Acute Coronary Syndrome, Undergoing Treatment with Dual Antiplatelet Therapy With Clopidogrel and Aspirin

1. Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreoti F, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2016;(37):267-315.10.1093/eurheartj/ehv32026320110Search in Google Scholar

2. Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC), Steg G, James SK, Atar D, Badano LP, Blomstrom-Lundqvist C, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012;(33):2569-2619.Search in Google Scholar

3. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox K.K. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl JMed. 2001 ;(345):494-502.10.1056/NEJMoa01074611519503Search in Google Scholar

4. Mega JL, Close SL, Wiviott SD, Shen L, Hocket RD, Brandt JT, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009;(360):354-62.10.1056/NEJMoa080917119106084Search in Google Scholar

5. Shuldiner AR, Vesely MR, Fisch A. CYP2C19 genotype and cardiovascular events. JAMA. 2012;307( 14): 1482; author reply 1484-5.10.1001/jama.2012.446Search in Google Scholar

6. Hulot JS, Collet JP, Cayla G, Silvain J, Allanic F, Bellemain-Appaix A, et al. CYP2C19 but not PON1 genetic variants influence clopidogrel pharmacokinetics, pharmacodynamics, and clinical efficacy in post-myocardial infarction patients. Circ Cardiovasc Interv. 2011;(4):422-8.10.1161/CIRCINTERVENTIONS.111.96302521972404Search in Google Scholar

7. Mega JL, Topol EJ, Sabatine MS. CYP2C19 genotype and cardiovascular events. JAMA. 2012;307( 14): 1482-3; author reply 1484-5.10.1001/jama.2012.44422496256Search in Google Scholar

8. Lanham KJ,()estreichJH,DunnSP, Steinhubl SR. Impact of genetic polymorphisms on clinical response to antithrombotics. Pharmacogenomics Pers Med.2010;(3):87-99.10.2147/PGPM.S9597351321123226045Search in Google Scholar

9. Tzveova R, Mitkova A, Paskaleva I, Kaneva R, Mitev V. [The role of genetic factors in determining the clinical efficacy of Clopidogrel]. Cardivascular diseases. 2013;44( 1): 16-29. Bulgarian.Search in Google Scholar

10. Savi P, Pereillo JM, Uzabiaga MF, Combalbert J, Picard C, Mafffand JP, et al. Identification and biological activity of the active metabolite of clopidogrel.Thromb Haemost. 2000;(84):891-6.10.1055/s-0037-1614133Search in Google Scholar

11. Kazui M,Nishiya Y, IshizukaT,HagiharaK, Farid NA, Okazaki O, et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos. 2010;38( 1 ):92-9.10.1124/dmd.109.02913219812348Search in Google Scholar

12. Taubert D, von Beckerath N, Grimbeig G, Lazar A, Jung N, Goeser T, et al. Impact of P-glycoprotein on clopidogrel absorption. Clin Pharmacol Then 2006;80(5):486-501.10.1016/j.clpt.2006.07.00717112805Search in Google Scholar

13. Gladding P, Webster M, Zeng I, Farrell H, Stewart J, Ruygrok Ret al. The pharmacogenetics and pharmacodynamics of clopidogrel response: an analysis from the PRINC (Plavix Response in Coronary Intervention) trial. JACC Cardiovasc Interv. 2008; 1 (6):620-7.10.1016/j.jcin.2008.09.00819463375Search in Google Scholar

14. Hulot JS, Bura A, Vi Hard E, Azizi M, Remones V, Goyenvalle C, et al. Cytochrome P4502C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood. 2006; 108(7):2244-7.10.1182/blood-2006-04-01305216772608Search in Google Scholar

15. Brandt JT, Close SL, Itunria SJ, Payne CD, Farid NA, Ernest II CS, et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost. 2007;5( 12):2429-36.10.1111/j.1538-7836.2007.02775.x17900275Search in Google Scholar

16. Harmsze A, van Werkum JW, Bouman HJ, Ruven HJ, Breet NJ, Ten Berg JM, et al. Besides CYP2C19*2, the variant allele CYP2C9*3 is associated with higher on-clopidogrel platelet reactivity in patients on dual antiplatelet therapy undergoing elective coronary stent implantation. Pharmacogenet Genomics. 2010;20( 1): 18-25.10.1097/FPC.0b013e328333dafe19934793Search in Google Scholar

17. Trenk D, Hochholzer W, Fromm MF, Chialda LE, Pahl A, Valina CM et al. Cytochrome P450 2C19 681 G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol. 2008;51(20): 1925-34.10.1016/j.jacc.2007.12.05618482659Search in Google Scholar

18. Shuldiner AR, O'Connell JR, Bliden KP, Gandhi A, Ryan K, Horenstein RB et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA. 2009;302(8):849-57.10.1001/jama.2009.1232364156919706858Search in Google Scholar

19. Simon T, Bhatt DL, Beigougnan L, Farenc C, Pearson K, Perrin L et al. Genetic polymorphisms and the impact of a higher clopidogrel dose regimen on active metabolite exposure and antiplatelet response in healthy subjects. Clin Pharmacol Then 2011;90(2):287-95.10.1038/clpt.2011.12721716274Search in Google Scholar

20. Scott SA, Sangkuhl K, Stein CM, Hulot JS, Mega JL, Roden DM, et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for cytochrome CYP2C19 genotype and clopidogrel therapy: 2013 Update. Clin Pharmacol Then 2013;94(3):317-323.10.1038/clpt.2013.105374836623698643Search in Google Scholar

21. Pcndichcva D, Tzvcova R, Dimitrova-KaramfOova A, Naydcnova G, Atanasov P, Mitkova A, ct al. Genetic polymorphisms in Clopidogrel and Accnocoumarol related genes and their frequencies in South-Hastem European populatioa ClinThcr. 2014;36(8 Suppl):c7.10.1016/j.clinthera.2014.05.025Search in Google Scholar

22. Akhlaghi A, Shirani S, Ziaic N, Pirhaji O, Yaran M, Shahverdi G, ct al. Cytochrome P450 2C19 Polymorphism in Iranian patients with Coronary Artery Disease. ARYA Athcrosclcr. 2011;7(3): 106-10.Search in Google Scholar

23. Namazi S, Kojuri J, Khalili A, Azarpira N. The impact of genetic polymorphisms of P2Y12, CYP3A5 and CYP2C19 on Clopidogrel response variability in Iranian patients. Biochcm Pharmacol 2012;83(7):903-8.10.1016/j.bcp.2012.01.00322265638Search in Google Scholar

24. Mega JL, Close SL, Wiviott SD, Shen L, Walker JR, Simon T, ct al. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after [treatment with clopidogrel and prasugrcl in the TRITON-T1MI 38 trial: a pharmacogcnctic analysis. Lancet. 2010;376(9749):1312-9.10.1016/S0140-6736(10)61273-1Search in Google Scholar

25. Simon T, Verstuyft C, Mary-Krause M, Qutcinch L, Drouct E, Mcncvcau N, ct al. Genetic determinants of response to Clopidogrel and cardiovascular Events. N Engl J Med. 2009;(360):363-75.10.1056/NEJMoa0808227Search in Google Scholar

26. Collet JP, Hulot JS, Pena A, Villard E, Esteve JB, Silvain J,ct al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 2009;373(9660):309-l 7.10.1016/S0140-6736(08)61845-0Search in Google Scholar

27. Sibbing D, Morath T, Braun S, Stegherr J, Mchilli J, Vogt W, ct al. Clopidogrel response status assessed with Multiplatc point-of-care analysis and the incidence and timing of stent thrombosis over six months following coronary stenting. Thromb Haemost. 2010;103( 1): 151-9.10.1160/TH09-05-0284Search in Google Scholar

28. Sibbing D, Schulz S, Braun S, Morath T, Stegherr J, Mchilli J, ct al. Antiplatclct effects ofclopidogrcl and bleeding in patients undergoing coronary stent placement. Thromb Haemost. 2010;8(2):250-6.10.1111/j.1538-7836.2009.03709.xSearch in Google Scholar

29. Sibbing D, Stegherr J, LatzW, Koch W, Mchilli J, Dorrlcr K, ct al. Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. Eur Heart J. 2009;30{8):916-22.10.1093/eurheartj/ehp041Search in Google Scholar

30. Mega JL, Simon T, Collet JP, Anderson JL, Antman EM, Bliden K, ct al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a metaanalysis. JAMA. 2010;304(16): 1821 -30.10.1001/jama.2010.1543Search in Google Scholar

31. Hulot JS, Collet JP, Silva in J, Pena A, Bellemain-Appaix A, Barthelemy O, et al. Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-tunction allele or proton pump inhibitor coadministration: a systematic meta-analysis. J Am Coll Cardiol. 2010;56(2): 134-43.10.1016/j.jacc.2009.12.071Search in Google Scholar

32. Hulot JS, Hajjar R, Montalescot G. Clopidogrel and CYP2C19 testing: ready for clinical prime time? Clin Chem. 2012;58( 1): 154-7.10.1373/clinchem.2011.165829Search in Google Scholar

33. Wallentin L, James S, Storey RF, Armstrong M, BarrattBJ, Borrow J,etal. Effect ofCYP2C 19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelol versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet. 2010;376(9749): 1320-8.10.1016/S0140-6736(10)61274-3Search in Google Scholar

34. Pare G, Mehta SR, YusufS, Anand SS, Connolly SJ, Hirsh J et al. Effects ofCYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med. 2010;363(18): 1704-14.10.1056/NEJMoa100841020979470Search in Google Scholar

35. Bauer T, Bouman HJ, van Werkum JW, Ford NF, ten Berg JM,Taubert D et al. Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis. BMJ. 201 l;(343):d4588.10.1136/bmj.d4588319156021816733Search in Google Scholar

36. Angiolillo DJ, Bernardo E, Sabate M, Jimenez-Quevedo P, Costa MA, Palazuelos J, et al. Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. J Am Coll Cardiol. 2007;50( 16): 1541-7.10.1016/j.jacc.2007.05.04917936152Search in Google Scholar

37. Cuisset T, Frere C, Quilici J, Poyet R, Gaborit B, Bali L, et al. Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose the PACA (Proton Pump Inhibitors And Clopidogrel Association) prospective randomized study. J Am Coll Cardiol. 2009;54{ 13): 1149-53.10.1016/j.jacc.2009.05.05019761935Search in Google Scholar

38. Gilard M, Amaud B, Comily JC, Le Gal G, Lacut K, Le Calvez G, et al. Influence of omeprazole on the anti platelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol. 2008;51 (3):256-60. 10.1016/j.jacc.2007.06.06418206732Search in Google Scholar